Physician profile
Daniel P Carriger
NPI 1306460605
$1,101.42
in general payments reported to CMS, 2019-2025
22 companies · $509 in 2025
The $509 reported for 2025 was more than what a typical Internal Medicine provider received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $12.20 · 2023: $225 · 2024: $355 · 2025: $509.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,089.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,089.22 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lilly USA, LLC | $144.97 | 2023-2025 | Jardiance, Mounjaro, Zepbound |
| Pfizer INC. | $137.36 | 2023-2025 | |
| Idorsia Pharmaceuticals US INC | $116.10 | 2023 | Quviviq |
| Bayer Healthcare Pharmaceuticals INC. | $88.72 | 2025 | |
| Astrazeneca Pharmaceuticals LP | $88.41 | 2024-2025 | Breztri, Farxiga, Airsupra |
| Medtronic, INC. | $64.79 | 2025 | Symplicity G3, Minimed 780g |
| Amgen INC. | $62.08 | 2023-2025 | Evenity, Repatha, Prolia |
| Astellas Pharma US INC | $53.39 | 2024-2025 | Veozah |
| Radius Health, INC. | $49.53 | 2024-2025 | Tymlos |
| Abbvie INC. | $43.51 | 2023-2024 | Qulipta |
| Phathom Pharmaceuticals, INC. | $41.25 | 2024 | Voquezna |
| Novo Nordisk INC | $30.77 | 2023-2024 | Ozempic, Rybelsus |
| Smith+Nephew, INC. | $21.84 | 2025 | Collagenase Santyl |
| Axsome Therapeutics, INC. | $21.55 | 2025 | Auvelity |
| Genzyme Corporation | $20.33 | 2024 |
Show all 22 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Seqirus USA INC | $19.91 | 2025 | Flucelvax, Fluad |
| Aurinia Pharma U.S., INC. | $18.77 | 2025 | Lupkynis |
| Glaxosmithkline, LLC. | $18.36 | 2025 | Trelegy Ellipta |
| Xeris Pharmaceuticals, INC. | $18.00 | 2024 | Gvoke Hypopen |
| Kiniksa Pharmaceuticals International, Plc | $16.06 | 2024 | Arcalyst |
| Philips North America LLC | $13.52 | 2024 | (5091) Amb Mon & Diag Und |
| Sanofi-Aventis U.S. LLC | $12.20 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Daniel Carriger listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.